Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAU_OP-11
- Development stage
- Unknown
- Lead developer
- Vectans Pharma
- Modality
- Small Molecules
- Administration
- Buccal
01
Overview
LAU_OP-11 is an investigational buccal tablet formulation being developed by Vectans Pharma for the management of chronic pain in cancer patients. The drug utilizes the proprietary Lauriad muco-adhesive technology, which consists of a small tablet that adheres to the gum or cheek, allowing for the controlled and sustained release of the active ingredient directly into the systemic circulation via the oral mucosa. This delivery method is intended to optimize the pharmacokinetic profile of the analgesic agent—likely an opioid—by providing rapid absorption and avoiding first-pass metabolism. As of late 2021, LAU_OP-11 is in Phase 1 clinical development.
Beyond the preview
Go deeper on LAU_OP-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAU_OP-11.